Callan Capital, LLC Buys Schwab Fundamental U.S. Large Company Index ETF, JPMorgan Ultra-Short Municipal Income ETF, Vanguard Mid-Cap ETF, Sells JPMorgan Ultra-Short Income ETF, Evofem Biosciences Inc

Author's Avatar
insider
Jan 21, 2022
Article's Main Image
La Jolla, CA, based Investment company Callan Capital, LLC (Current Portfolio) buys Schwab Fundamental U.S. Large Company Index ETF, JPMorgan Ultra-Short Municipal Income ETF, Vanguard Mid-Cap ETF, PowerShares FTSE RAFI US 1500 Small-Mid Portfolio, SPDR Portfolio Developed World ex-US ETF, sells JPMorgan Ultra-Short Income ETF, Evofem Biosciences Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Callan Capital, LLC. As of 2021Q4, Callan Capital, LLC owns 132 stocks with a total value of $688 million. These are the details of the buys and sells.

For the details of Callan Capital, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/callan+capital%2C+llc/current-portfolio/portfolio

These are the top 5 holdings of Callan Capital, LLC
  1. Schwab U.S. Broad Market ETF (SCHB) - 980,579 shares, 16.11% of the total portfolio. Shares added by 1.63%
  2. Schwab International Equity ETF (SCHF) - 1,760,106 shares, 9.94% of the total portfolio. Shares added by 8.94%
  3. Goldman Sachs ActiveBeta U.S. Large Cap Equity ETF (GSLC) - 689,196 shares, 9.53% of the total portfolio. Shares added by 0.58%
  4. Invesco FTSE RAFI US 1000 ETF (PRF) - 227,433 shares, 5.68% of the total portfolio. Shares reduced by 1.94%
  5. Schwab Fundamental International Large Company Ind (FNDF) - 1,134,705 shares, 5.36% of the total portfolio. Shares added by 3.39%
New Purchase: SPDR Portfolio Developed World ex-US ETF (SPDW)

Callan Capital, LLC initiated holding in SPDR Portfolio Developed World ex-US ETF. The purchase prices were between $34.8 and $37.35, with an estimated average price of $36.26. The stock is now traded at around $35.220000. The impact to a portfolio due to this purchase was 0.2%. The holding were 37,340 shares as of 2021-12-31.

New Purchase: Vanguard S&P 500 ETF (VOO)

Callan Capital, LLC initiated holding in Vanguard S&P 500 ETF. The purchase prices were between $392.77 and $439.01, with an estimated average price of $421.15. The stock is now traded at around $402.690000. The impact to a portfolio due to this purchase was 0.18%. The holding were 2,801 shares as of 2021-12-31.

New Purchase: Invesco FTSE RAFI Developed Markets ex-U.S. ETF (PXF)

Callan Capital, LLC initiated holding in Invesco FTSE RAFI Developed Markets ex-U.S. ETF. The purchase prices were between $44.73 and $48.11, with an estimated average price of $46.88. The stock is now traded at around $47.620000. The impact to a portfolio due to this purchase was 0.17%. The holding were 24,987 shares as of 2021-12-31.

New Purchase: Schwab U.S. Small-Cap ETF (SCHA)

Callan Capital, LLC initiated holding in Schwab U.S. Small-Cap ETF. The purchase prices were between $97.28 and $109.61, with an estimated average price of $103.15. The stock is now traded at around $91.440000. The impact to a portfolio due to this purchase was 0.15%. The holding were 9,937 shares as of 2021-12-31.

New Purchase: Schwab Fundamental Emerging Markets Large Company (FNDE)

Callan Capital, LLC initiated holding in Schwab Fundamental Emerging Markets Large Company . The purchase prices were between $29.56 and $32.29, with an estimated average price of $31.11. The stock is now traded at around $31.700000. The impact to a portfolio due to this purchase was 0.15%. The holding were 32,682 shares as of 2021-12-31.

New Purchase: Schwab U.S. Tips ETF (SCHP)

Callan Capital, LLC initiated holding in Schwab U.S. Tips ETF. The purchase prices were between $61.62 and $63.22, with an estimated average price of $62.39. The stock is now traded at around $61.370000. The impact to a portfolio due to this purchase was 0.13%. The holding were 14,564 shares as of 2021-12-31.

Added: Schwab Fundamental U.S. Large Company Index ETF (FNDX)

Callan Capital, LLC added to a holding in Schwab Fundamental U.S. Large Company Index ETF by 22.94%. The purchase prices were between $54.17 and $58.73, with an estimated average price of $56.79. The stock is now traded at around $56.630000. The impact to a portfolio due to this purchase was 0.84%. The holding were 525,875 shares as of 2021-12-31.

Added: JPMorgan Ultra-Short Municipal Income ETF (JMST)

Callan Capital, LLC added to a holding in JPMorgan Ultra-Short Municipal Income ETF by 54.91%. The purchase prices were between $50.97 and $51.07, with an estimated average price of $51.02. The stock is now traded at around $50.900000. The impact to a portfolio due to this purchase was 0.39%. The holding were 147,057 shares as of 2021-12-31.

Added: Vanguard Mid-Cap ETF (VO)

Callan Capital, LLC added to a holding in Vanguard Mid-Cap ETF by 224.19%. The purchase prices were between $236.12 and $260.25, with an estimated average price of $250.07. The stock is now traded at around $229.350000. The impact to a portfolio due to this purchase was 0.28%. The holding were 10,682 shares as of 2021-12-31.

Added: PowerShares FTSE RAFI US 1500 Small-Mid Portfolio (PRFZ)

Callan Capital, LLC added to a holding in PowerShares FTSE RAFI US 1500 Small-Mid Portfolio by 37.19%. The purchase prices were between $180.6 and $200.41, with an estimated average price of $190.11. The stock is now traded at around $175.950700. The impact to a portfolio due to this purchase was 0.23%. The holding were 30,468 shares as of 2021-12-31.

Added: Schwab Emerging Markets Equity ETF (SCHE)

Callan Capital, LLC added to a holding in Schwab Emerging Markets Equity ETF by 93.74%. The purchase prices were between $28.67 and $31.28, with an estimated average price of $30.07. The stock is now traded at around $29.860000. The impact to a portfolio due to this purchase was 0.15%. The holding were 71,233 shares as of 2021-12-31.

Added: Microsoft Corp (MSFT)

Callan Capital, LLC added to a holding in Microsoft Corp by 40.98%. The purchase prices were between $283.11 and $343.11, with an estimated average price of $325.12. The stock is now traded at around $296.030000. The impact to a portfolio due to this purchase was 0.14%. The holding were 9,798 shares as of 2021-12-31.

Sold Out: Evofem Biosciences Inc (EVFM)

Callan Capital, LLC sold out a holding in Evofem Biosciences Inc. The sale prices were between $0.37 and $0.77, with an estimated average price of $0.56.



Here is the complete portfolio of Callan Capital, LLC. Also check out:

1. Callan Capital, LLC's Undervalued Stocks
2. Callan Capital, LLC's Top Growth Companies, and
3. Callan Capital, LLC's High Yield stocks
4. Stocks that Callan Capital, LLC keeps buying
Rating:
NaN / 5 ( votes)
Author's Avatar
WRITTEN BY

GuruFocus Screeners

Related Articles